Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration

By Nov 15, 2018

According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.

FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds

By Nov 14, 2018

Reports of pump failure, dosing errors, as well as other possible safety issues have prompted the Agency to issue the alert to make prescribers aware of the dangers associated with using medications not approved for intrathecal use.

Oralair Approved for Younger Patients With Grass Pollen Allergy

By Nov 14, 2018

Oralair is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for any of the 5 grass species contained in this product.

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

By Nov 12, 2018

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child-Pugh class A liver impairment.

Updated Infant Administration Procedure Approved for Nityr

By Nov 12, 2018

The labeling now states that a caregiver may disintegrate the Nityr tablet in an oral syringe up to 24 hours before administration.

More Articles by Diana Ernst, RPh